Please assess the completion status of the following clinical trial:

Trial Title: Local Injection Under US Control in GTPS.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients complaining of lateral hip pain for more than 1 month.~2. NRS lateral hip pain score ≥ 4 in the preceding week.~3. Failure of another standard treatment:~   * Physiotherapy: local therapy or a stretching program, or~  * Analgesic treatment (minimum of 5 days of consecutive therapy, including, but not limited to, NSAIDs).~4. Typical lateral hip pain reproduced by palpation of the greater trochanter~Exclusion Criteria:~1. Age younger than 18 years old~2. Concomitant local surgical intervention for tumours, infection or fracture, based on clinical history and physical examination~3. Previous ipsilateral prosthetic hip surgery~4. Scheduled ipsilateral hip surgery within 3 months~5. Fibromyalgia (diagnosis established by a rheumatologist)~6. Flair of chronic inflammatory joint disease (as defined by a rheumatologist)~7. Skin lesions at the injection site~8. Allergy to one of the studied drugs~9. Anticoagulation with internal normalized ration (INR) \>3~10. Blood coagulation disorder, such as haemophilia.~11. Serious and uncontrolled psychiatric disease (as assessed by the clinician as a contraindication for steroid)~12. Other contraindications to steroid use, such as:~    * uncontrolled diabetes (non-fasting blood glucose \> 10 mmol/L)~   * unstable hypertension (systolic pressure \> 160mmHg or diastolic pressure \> 100mmHg), or~   * open or closed angle glaucoma.~13. Requirement for systemic steroids (including steroid injections) or dose modification of disease modifying anti-rheumatic drugs during the preceding three months. Oral corticosteroids (\< 10mg / day of Prednisone or equivalent) will be permitted providing that the dose has been stable for 4 weeks prior to inclusion and that the patient is expected to remain on the baseline dose for the duration of the study.~14. Presence of a pacemaker or other metallic object that constitutes a CI to MRI, or severe claustrophobia~15. Pregnant women (according to a pregnancy test) or nursing (breastfeeding) mothers.~16. Unwillingness or inability to give informed consent.~17. Unavailability for follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rapidocain and bethametsaone (Type: ACTIVE_COMPARATOR): Rapidocain and Bethametsaone :~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)
- sterile saline (Type: PLACEBO_COMPARATOR): Placebo arm with 5ml of sterile saline (NaCl) solution

Based on this trial design, predict the completion outcome and termination type (if applicable).